| Expression pattern: |
UP |
| Associated gene: |
GCLM, Nrf2, GPX4, xCT, GCLC, FTH1 |
| Associated microRNA: |
miR-145-5p |
| Biological function: |
Promotes MMQ cell proliferation and tumor growth, attenuates cabergoline efficacy, and induces resistance to CAB-induced ferroptosis in prolactinoma models. |
| Molecular mechanism: |
circOMA1 acts as a miR-145-5p sponge to regulate GCLM expression and inhibits ferroptosis through promotion of the Nrf2/GPX4 axis, thereby reducing cabergoline efficacy. |
| Biological pathway or process: |
proliferation (promotes); ferroptosis (inhibits); drug resistance (promotes); ceRNA regulation (other); other pathway/process (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Transfection; CCK8; Colony Formation Assay; EdU Staining; Western Blot; IF (Immunofluorescence); IHC (Immunohistochemistry); Luciferase Reporter Assay; Bioinformatics Analysis; In Vivo Animal Model |
| Clinical significance: |
High circOMA1 expression is associated with DA-resistant prolactinoma and elevated prolactin levels, and circOMA1 may be a therapeutic target for individualized treatment of DA-resistant prolactinoma patients. |
| Description: |
circOMA1 is up-regulated in DA-resistant prolactinoma tissues and promotes prolactinoma cell growth in vitro and in a xenograft model. Mechanistically, circOMA1 acts as a miR-145-5p sponge to regulate GCLM and promotes the Nrf2/GPX4 ferroptosis-resistance program, thereby attenuating cabergoline-induced ferroptosis and reducing cabergoline efficacy. |
| Confidence score: |
0.713 |